← All candidates
Three insider buys in the last year — $764.9K in all.
33 filings on record.
ADVMAdverum Biotechnologies, Inc.
—
Three insider buys in the last year — $764.9K in all.
Nothing in the last fortnight.
No price data yet — the yfinance scanner hasn't produced bars for ADVM.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO, PRESIDENT AND DIRECTOR
Fischer Laurent
Bought $506.9K on Dec 8 — 117,614 sh @ $4.31, held direct, 58% of their stake.
No completed positions to measure
CHIEF OPERATING OFFICER
Soparkar Peter
Bought $211.0K on Dec 5 — 50,000 sh @ $4.22, held direct, 62% of their stake.
No completed positions to measure
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
28 more transactions on Pro →Context
Coverage
Adverum Biotechnologies: Q3 Earnings SnapshotAssociated Press Finance · 11-12Eli Lilly buys Adverum in eye disease gene therapy puntPharmaceutical Technology · 10-27Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho SaysMT Newswires · 10-24Eli Lilly to Acquire Eye Gene Therapy Developer Adverum BiotechnologiesMT Newswires · 10-24
The file stays open
33 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice